Product news and why it matters for Baxter International (BAX) shareholders

Baxter International (BAX) is back in focus after using the AORN Global Surgical Conference & Expo to showcase its AAT XR spine surgical table and Dynamo Series smart stretcher to perioperative clinicians.

Both products target operating room efficiency and patient handling, tying directly into Baxter’s Medical Products & Therapies and Healthcare Systems & Technologies segments, which together generated US$8,370m of the company’s US$11,244m revenue.

Despite the AORN product showcase, Baxter’s recent trading reflects a mixed picture, with a 9.5% 1 month share price return and a 3.1% 1 day move higher, set against a 34.4% 1 year total shareholder return decline and a 76.4% 5 year total shareholder return decline. This suggests short term momentum is improving while long term value creation has been weak.

If you want to see how other healthcare names are positioned around similar themes of technology and efficiency, this is a good moment to scan 35 healthcare AI stocks.

With Baxter trading at US$18.71, sitting on multi year total return declines and screening on some models at roughly a 32% intrinsic discount, you have to ask: is this a reset entry point, or is the market already assuming a rebound?

Most Popular Narrative: 13.5% Undervalued

With Baxter International closing at $18.71 against a most followed fair value estimate of $21.63, the current pricing sits below that narrative anchor and puts extra weight on the assumptions behind it.

Ongoing portfolio optimization efforts, including divestitures, cost reductions, and a commitment to eliminate stranded costs by 2027, aim to streamline operations, improve efficiency, and drive net margin improvement, which should be reflected in future earnings growth.

Want to see what really drives that gap between price and fair value? The core story leans on steadier revenue, rising margins, and a richer earnings profile over time.

Result: Fair Value of $21.63 (UNDERVALUED)

However, there are still clear pressure points, including ongoing margin compression and quality or legal issues around infusion pumps, which could limit how quickly the story improves.

Next Steps

Given the mix of concern and optimism running through this story, it makes sense to look at the full picture yourself and move quickly while sentiment is still split. Start with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Baxters story caught your attention, do not stop here. Use a targeted screener to surface other opportunities that match the kind of portfolio you want.

• Target value first by scanning companies that look mispriced on quality and fundamentals using the 59 high quality undervalued stocks.
• Prioritize resilience by searching for companies with strong finances and steady profiles through the solid balance sheet and fundamentals stocks screener (42 results).
• Spot under the radar potential by reviewing a screener containing 23 high quality undiscovered gems before the crowd catches up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.